BMC: Improved accuracy of intraocular lens power calculation by preope…
2026-01-22
Abstract
Background: To evaluate the effects of pretreatment for dry eye disease (DED) on the accuracy of intraocular lens
(IOL) power calculation.
Methods: Patients who underwent uneventful cataract surgery were included in the study. IOL power was determined
using the SRK/T and Barrett Universal II (Barrett) formulas. The patients were divided into non-pretreatment and
pretreatment groups, and those in the pretreatment group were treated with topical 0.5% loteprednol etabonate and
0.05% cyclosporin A for 2 weeks prior to cataract surgery. Ocular biometry was performed in all groups within 2 days
before surgery. The mean prediction error, mean absolute error (MAE), and proportions of refractive surprise were
compared between the non-pretreatment and pretreatment groups at 1 month postoperatively. Refractive surprise
was defined as MAE ≥ 0.75D.
Results: In a total of 105 patients, 52 (52 eyes) were in the non-pretreatment group and 53 (53 eyes) in the pretreatment
group. The MAE was 0.42 ± 0.33, 0.38 ± 0.34 (SRK/T, Barrett) and 0.23 ± 0.19, 0.24 ± 0.19 in the non-pretreatment
and pretreatment groups, respectively (p < 0.001/=0.008). The number of refractive surprises was also significantly
lower in the pretreatment group. [non-pretreatment/pretreatment: 9/2 (SRK/T); 8/1 (Barrett); p = 0.024/0.016]. Pretreatment
of DED was related to a reduction in postoperative refractive surprise. [SRK/T/Barrett: OR = 0.18/0.17 (95%
CI: 0.05–0.71/0.05–0.60), p = 0.014/0.006].
Conclusions: The accuracy of IOL power prediction can be increased by actively treating DED prior to cataract
surgery.
Background: To evaluate the effects of pretreatment for dry eye disease (DED) on the accuracy of intraocular lens
(IOL) power calculation.
Methods: Patients who underwent uneventful cataract surgery were included in the study. IOL power was determined
using the SRK/T and Barrett Universal II (Barrett) formulas. The patients were divided into non-pretreatment and
pretreatment groups, and those in the pretreatment group were treated with topical 0.5% loteprednol etabonate and
0.05% cyclosporin A for 2 weeks prior to cataract surgery. Ocular biometry was performed in all groups within 2 days
before surgery. The mean prediction error, mean absolute error (MAE), and proportions of refractive surprise were
compared between the non-pretreatment and pretreatment groups at 1 month postoperatively. Refractive surprise
was defined as MAE ≥ 0.75D.
Results: In a total of 105 patients, 52 (52 eyes) were in the non-pretreatment group and 53 (53 eyes) in the pretreatment
group. The MAE was 0.42 ± 0.33, 0.38 ± 0.34 (SRK/T, Barrett) and 0.23 ± 0.19, 0.24 ± 0.19 in the non-pretreatment
and pretreatment groups, respectively (p < 0.001/=0.008). The number of refractive surprises was also significantly
lower in the pretreatment group. [non-pretreatment/pretreatment: 9/2 (SRK/T); 8/1 (Barrett); p = 0.024/0.016]. Pretreatment
of DED was related to a reduction in postoperative refractive surprise. [SRK/T/Barrett: OR = 0.18/0.17 (95%
CI: 0.05–0.71/0.05–0.60), p = 0.014/0.006].
Conclusions: The accuracy of IOL power prediction can be increased by actively treating DED prior to cataract
surgery.
